Peptide profile
Published Data as of
Studies in people tested Semax after ischemic stroke, on blood lipids in psoriasis, and on brain scans in healthy volunteers.1,2,3,4 As of November 15, 2026, PepBank holds 12 publications with findings in people and 99 with findings in animals.5 Its records list 0 registered trials that test Semax.5 PepBank's regulatory record shows Semax approved in Russia only, registered as Семакс.6
PepBank's regulatory record shows Semax approved in Russia only, registered as Семакс.6 In Russia, Семакс is a prescription-only medicine in nasal drops from the holder Peptogen.6 One listed indication is the acute period of moderate to severe ischemic stroke, as part of combined therapy.6
As of November 15, 2026, PepBank holds 12 publications with findings in people and 99 with findings in animals.5 It also holds 24 publications with laboratory findings in cells or tissue.5 Its records list 0 registered trials that test Semax.5
Semax is one of the peptides in PepBank, with 130 studies that report results.5 The Semax studies hold 36 findings in people, against 331 findings in animals.5
In a trial in patients with acute hemispheric ischemic stroke, doctors added Semax to combined intensive therapy. It increased the regress of general cerebral disorders compared with conventional therapy.1 The same trial in patients found more regress of focal, especially motor, disorders.1
In another trial in adults after ischemic stroke, Semax raised plasma brain-derived neurotrophic factor (BDNF) levels. The levels stayed high for the whole study, regardless of when rehabilitation started.2 In that trial in people, Semax and high BDNF levels made recovery faster and better on the Barthel index.2
In a trial in patients with psoriasis and metabolic syndrome, doctors added intranasal Semax to conventional therapy. It lowered initially elevated total cholesterol, triglycerides and low-density lipoprotein (LDL) cholesterol.3 In the same patients, it raised initially reduced high-density lipoprotein (HDL) cholesterol, while standard treatment had no significant effect.3
In a study in healthy people, intranasal Semax was linked to a greater volume of the rostral part of the default mode network. This showed on resting state functional MRI (fMRI), compared with placebo.4 In another study in healthy people, Semax injection changed resting-state connectivity between the right amygdala and the right temporal cortex.7
The listed findings in people come from non-randomized trials, observational studies and one study of another design. None of them is a randomized controlled trial.1,2,3,4,7,8 PepBank's records list 0 registered trials that test Semax.5
In the acute stroke trial in patients, the researchers compared Semax with conventional therapy, without random assignment.1 So the results in patients describe the people in these studies. They do not show how far the effects reach.1,2,3 PepBank lists the stroke, lipid and brain scan findings under the evidence class for people.1,2,3,4
In a trial in patients with optic nerve disease, adding Semax to the therapeutic complex improved visual functions.9 In those patients, visual acuity and color vision also improved.9 In a trial in patients with non-proliferative diabetic retinopathy, both Semax groups showed positive changes in visual characteristics.10 In those patients, the most pronounced and long-standing effect came with endonasal Semax electrophoresis.10
In a trial in patients with refractory peptic ulcers, the patients received intranasal Semax with traditional drugs.11 Ulcers healed in 89.5% of these patients, versus 30.8% in the control group.11 In patients with motor neuron disease, Semax did not change the course of chronic partial denervation, though quality of life improved.12
In an observational study in patients with cerebrovascular insufficiency, Semax had a minor percent of side effects.8 The same study in patients found Semax well tolerated, including by older age groups.8 In a study in patients with posthypoxic encephalopathy, an electroencephalogram (EEG) showed episodes of paroxysmal activity after Semax injection in some cases.13
As of November 15, 2026, PepBank holds 99 publications with findings in animals for Semax, with 331 findings.5 It holds 12 publications with findings in people.5 In rats after cerebral ischemia, Semax enhanced transcription of the Bdnf gene in the cortex.14 In rats, Semax also enhanced transcription of TrkA and TrkC in the cortex.14
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated